531371 Sigma-AldrichS1P Receptor 2 Agonist, CYM-5520 - CAS 1449747-00-5 - Calbiochem
A potent, selective, allosteric agonist of sphingosine-1-phosphate receptor 2 (S1PR2; EC₅₀ = 480 nM).
More>> A potent, selective, allosteric agonist of sphingosine-1-phosphate receptor 2 (S1PR2; EC₅₀ = 480 nM). Less<<Synonyms: S1PR2 Agonist, CYM-5520, Sphingosine-1-Phosphate Receptor 2 Agonist, CYM 5520, EDG5 Agonist
Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| CAS # | Empirical Formula |
|---|---|
| 1449747-00-5 | C₂₁H₁₉N₃O₂ |
Pricing & Availability
| Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
|---|---|---|---|---|---|---|
| 5.31371.0001 |
|
Glass bottle | 10 mg |
|
— |
| References | |
|---|---|
| References | Satsu, H., et al. 2013. Bioorg. Med. Chem. 21, 5373. |
| Product Information | |
|---|---|
| CAS number | 1449747-00-5 |
| Form | Off-white solid |
| Hill Formula | C₂₁H₁₉N₃O₂ |
| Chemical formula | C₂₁H₁₉N₃O₂ |
| Reversible | Y |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | S1PR2 |
| Purity | ≥98% by HPLC |
| Physicochemical Information |
|---|
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| 5.31371.0001 | 04055977260298 |
Documentation
S1P Receptor 2 Agonist, CYM-5520 - CAS 1449747-00-5 - Calbiochem SDS
| Title |
|---|
References
| Reference overview |
|---|
| Satsu, H., et al. 2013. Bioorg. Med. Chem. 21, 5373. |
Brochure
| Title |
|---|
| NPI Flyer- Epigenetics and Nuclear Function Feature |
| New Products - Antibodies, Small Molecule, Inhibitors |
Technical Info
| Title |
|---|
| White Paper: Further considerations of antibody validation and usage. |


